Last update 20 Mar 2025

Nangibotide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
CardioTREM, Motrem, TREM-like-transcript-1-derived-peptide
+ [1]
Target
Action
inhibitors
Mechanism
TREM1 inhibitors(Triggering receptor expressed on myeloid cells 1 inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC54H82N14O22S2
InChIKeyHZQYFECPKQJXFX-DAHMAOPXSA-N
CAS Registry2014384-91-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
Belgium
06 Jul 2020
Shock, SepticPhase 3
Netherlands
03 Jul 2017
Myocardial InfarctionPhase 3
France
-
Shock, SepticPhase 2
Spain
03 Jul 2017
Shock, SepticPhase 2
Belgium
03 Jul 2017
Shock, SepticPhase 2
France
03 Jul 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
355
(egnsekzkjd) = fwpkqxjkhc tyelqbbgmm (iqdivfolrt )
Negative
01 Oct 2023
(egnsekzkjd) = tohgolknfu tyelqbbgmm (iqdivfolrt )
Phase 2
220
uhixowslxe(sfaripclqq): odds ratio = 1.79 (95% CI, 1.02 - 3.14), P-Value = 0.043
Positive
01 Jun 2023
Placebo
Phase 2
220
xreqabdxkr(hfcibkgqch): P-Value = 0.040
Positive
25 Oct 2022
Placebo
Phase 2
-
(nuvizjevew) = the benefit of nangibotide high dose treatment versus placebo was clinically and statistically significant at higher concentrations of sTREM-1, representing about 50% of the study population ivwpuwmogx (hwvitzclpy )
Positive
13 Oct 2022
Standard of Care
Phase 1
27
mibpoynprt(xoqkoezxcf) = There were only few adverse events and they were mild in severity and considered unrelated to treatment kymomdzkvj (oielzgvrnb )
-
01 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free